By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

The CDC's expert panel explores narrowing COVID-19 booster shot guidelines to focus on high-risk groups. Despite concerns ...

Notes from a recent meeting of the CDC’s Advisory Committee on Immunization Practices’ COVID-19 Work Group show health ...

The U.S. Centers for Disease Control and Prevention’s outside panel of vaccine experts on Tuesday discussed narrowing ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The CDC's vaccine committee will convene for a two-day meeting this week to consider recommendations on vaccines, including ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...